Relay Therapeutics (RLAY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $16.28, -5.90% vs the prior close of $17.30.
- Volume 2.37M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RLAY slides 5.9% to $16.28, a 3-month low. Closed at $16.28, -5.90% vs the prior close of $17.30. Day range $16.13–$17.17, opened at $17.17.
RLAY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RLAY slides 5.9% to $16.28, a 3-month low
- Closed at $16.28, -5.90% vs the prior close of $17.30. Day range $16.13–$17.17, opened at $17.17.
- Volume was 2.37M shares, 0.8x its 50-day average of 2.95M.
- Price is -13.6% vs its 50-day average ($18.84) and +12.5% vs its 200-day average ($14.48).
- 52-week range $5.95–$21.27; today's close sits at 67% of that range, 23.5% below the 52-week high.
Oct 15, 2026 — RLAY rises 1.4% to $17.30
- Closed at $17.30, +1.41% vs the prior close of $17.06. Day range $17.07–$17.56, opened at $17.15.
- Volume was 2.12M shares, 0.7x its 50-day average of 2.94M.
- Price is -8.5% vs its 50-day average ($18.91) and +19.8% vs its 200-day average ($14.44).
- 52-week range $5.95–$21.27; today's close sits at 74% of that range, 18.7% below the 52-week high.
Oct 14, 2026 — RLAY dips 1.7% to $17.06, a 3-month low
- Closed at $17.06, -1.73% vs the prior close of $17.36. Day range $16.90–$17.77, opened at $17.02.
- Volume was 2.94M shares, 1.0x its 50-day average of 2.92M.
- Price is -10.0% vs its 50-day average ($18.96) and +18.5% vs its 200-day average ($14.39).
- 52-week range $5.85–$21.27; today's close sits at 73% of that range, 19.8% below the 52-week high.
Oct 13, 2026 — RLAY slides 3.4% to $17.36, a 3-month low
- Closed at $17.36, -3.45% vs the prior close of $17.98. Day range $17.27–$17.93, opened at $17.84.
- Volume was 1.71M shares, 0.6x its 50-day average of 2.92M — lighter than usual.
- Price is -8.7% vs its 50-day average ($19.01) and +21.0% vs its 200-day average ($14.35).
- 52-week range $5.85–$21.27; today's close sits at 75% of that range, 18.4% below the 52-week high.
Oct 12, 2026 — RLAY rises 0.6% to $17.98
- Closed at $17.98, +0.56% vs the prior close of $17.88. Day range $17.53–$18.33, opened at $17.77.
- Volume was 2.09M shares, 0.7x its 50-day average of 2.92M.
- Price is -5.6% vs its 50-day average ($19.04) and +25.7% vs its 200-day average ($14.31).
- 52-week range $5.85–$21.27; today's close sits at 79% of that range, 15.5% below the 52-week high.
Oct 9, 2026 — RLAY rises 2.7% to $17.88
- Closed at $17.88, +2.70% vs the prior close of $17.41. Day range $17.01–$18.50, opened at $17.01.
- Volume was 1.76M shares, 0.6x its 50-day average of 2.92M.
- Price is -6.2% vs its 50-day average ($19.06) and +25.4% vs its 200-day average ($14.26).
- 52-week range $5.85–$21.27; today's close sits at 78% of that range, 15.9% below the 52-week high.
Oct 8, 2026 — RLAY slides 3.0% to $17.41, a 3-month low, 3 down days in a row
- Closed at $17.41, -3.01% vs the prior close of $17.95. Day range $16.87–$17.97, opened at $17.71.
- Volume was 4.33M shares, 1.5x its 50-day average of 2.87M.
- Price is -8.8% vs its 50-day average ($19.09) and +22.5% vs its 200-day average ($14.21).
- 52-week range $5.83–$21.27; today's close sits at 75% of that range, 18.1% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — RLAY slides 4.2% to $17.95
- Closed at $17.95, -4.22% vs the prior close of $18.74. Day range $17.85–$18.54, opened at $18.40.
- Volume was 3.43M shares, 1.2x its 50-day average of 2.86M.
- Price is -6.1% vs its 50-day average ($19.11) and +26.7% vs its 200-day average ($14.17).
- 52-week range $5.47–$21.27; today's close sits at 79% of that range, 15.6% below the 52-week high.
Oct 6, 2026 — RLAY slides 3.4% to $18.74
- Closed at $18.74, -3.35% vs the prior close of $19.39. Day range $18.17–$19.50, opened at $19.50.
- Volume was 3.88M shares, 1.4x its 50-day average of 2.87M.
- Price is -2.0% vs its 50-day average ($19.11) and +32.8% vs its 200-day average ($14.12).
- 52-week range $5.47–$21.27; today's close sits at 84% of that range, 11.9% below the 52-week high.
Oct 5, 2026 — RLAY rises 2.3% to $19.39, a 1-month high, 3 up days in a row
- Closed at $19.39, +2.27% vs the prior close of $18.96. Day range $18.28–$19.40, opened at $19.00.
- Volume was 2.94M shares, 1.0x its 50-day average of 2.85M.
- Price is +1.5% vs its 50-day average ($19.11) and +37.9% vs its 200-day average ($14.06).
- 52-week range $5.26–$21.27; today's close sits at 88% of that range, 8.8% below the 52-week high.
- That makes 3 straight gains.
Oct 2, 2026 — RLAY rises 2.5% to $18.96
- Closed at $18.96, +2.54% vs the prior close of $18.49. Day range $18.60–$19.13, opened at $18.71.
- Volume was 2.77M shares, 1.0x its 50-day average of 2.82M.
- Price is -0.7% vs its 50-day average ($19.09) and +35.3% vs its 200-day average ($14.01).
- 52-week range $5.16–$21.27; today's close sits at 86% of that range, 10.9% below the 52-week high.
RLAY latest news & SEC filings
Every SEC filing by or about RLAY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Patel Sanjiv sold 48,199 shares at $18.10 (≈$872.40K) on Oct 7, 2026; now holds 471,301
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Catinazzo Thomas sold 17,511 shares at $18.58 (≈$325.35K) on Oct 6, 2026; now holds 105,340
- Catinazzo Thomas sold 206 shares at $19.26 (≈$3.97K) on Oct 6, 2026; now holds 105,134
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 6, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bergstrom Donald A sold 8,530 shares at $18.97 (≈$161.81K) on Sep 8, 2026
- Bergstrom Donald A sold 8,530 shares at $18.97 (≈$161.81K) on Sep 8, 2026
- Bergstrom Donald A sold 8,530 shares at $18.97 (≈$161.81K) on Sep 8, 2026
- Bergstrom Donald A sold 8,530 shares at $18.97 (≈$161.81K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Catinazzo Thomas sold 17,717 shares at $18.94 (≈$335.56K) on Sep 8, 2026
- Catinazzo Thomas sold 17,717 shares at $18.94 (≈$335.56K) on Sep 8, 2026
- Catinazzo Thomas sold 17,717 shares at $18.94 (≈$335.56K) on Sep 8, 2026
- Catinazzo Thomas sold 17,717 shares at $18.94 (≈$335.56K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $350.00K (prior year $677.00K) (-48.3% vs Jun 30, 2025)
- Net income: -$83.71M (prior year -$70.38M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.41 (prior year -$0.41) ( vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade RLAY
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.00% (largest 6.8%). That is a volatile stock.
- Liquidity: about 2.97M shares (≈$48.35M) trade per day on average.
- 52-week position: $16.28 vs a range of $5.95–$21.27 (67% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Sanjiv Patel sold 48,199 shares on Sep 8, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 9, 2026.
- Share count: 219.14M shares outstanding (Jul 31, 2026), +27.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
RLAY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 17.17 | 17.17 | 16.13 | 16.28 | 2.37M |
| Oct 15, 2026 | 17.15 | 17.56 | 17.07 | 17.30 | 2.12M |
| Oct 14, 2026 | 17.02 | 17.77 | 16.90 | 17.06 | 2.94M |
| Oct 13, 2026 | 17.84 | 17.93 | 17.27 | 17.36 | 1.71M |
| Oct 12, 2026 | 17.77 | 18.33 | 17.53 | 17.98 | 2.09M |
| Oct 9, 2026 | 17.01 | 18.50 | 17.01 | 17.88 | 1.76M |
| Oct 8, 2026 | 17.71 | 17.97 | 16.87 | 17.41 | 4.33M |
| Oct 7, 2026 | 18.40 | 18.54 | 17.85 | 17.95 | 3.43M |
| Oct 6, 2026 | 19.50 | 19.50 | 18.17 | 18.74 | 3.88M |
| Oct 5, 2026 | 19.00 | 19.40 | 18.28 | 19.39 | 2.94M |
| Oct 2, 2026 | 18.71 | 19.13 | 18.60 | 18.96 | 2.77M |
| Oct 1, 2026 | 18.02 | 19.08 | 17.86 | 18.49 | 2.82M |
| Sep 30, 2026 | 18.39 | 18.72 | 17.93 | 18.05 | 2.78M |
| Sep 29, 2026 | 17.65 | 18.48 | 17.51 | 18.36 | 3.59M |
| Sep 28, 2026 | 17.10 | 17.88 | 17.05 | 17.69 | 1.84M |
| Sep 25, 2026 | 17.94 | 18.01 | 17.42 | 17.47 | 2.98M |
| Sep 24, 2026 | 18.09 | 18.09 | 17.41 | 17.73 | 3.67M |
| Sep 23, 2026 | 19.15 | 19.23 | 17.22 | 18.03 | 4.71M |
| Sep 22, 2026 | 18.43 | 19.48 | 18.21 | 19.35 | 3.63M |
| Sep 21, 2026 | 19.07 | 19.17 | 18.05 | 18.19 | 3.03M |
About Relay Therapeutics
Relay Therapeutics (RLAY) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1812364.
RLAY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Alexis Borisy | Director | Jun 10, 2026 |
| Lonnel Coats | Director | Jun 10, 2026 |
| Habib J Dable | Director | Jun 10, 2026 |
| Linda A Hill | Director | Jun 10, 2026 |
| Douglas S Ingram | Director | Jun 10, 2026 |
| Claire Mazumdar | Director | Jun 10, 2026 |
| Mark Murcko | Director | Jun 10, 2026 |
| Sanjiv Patel | President and CEO | Sep 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Donald A Bergstrom | President, R&D | Sep 9, 2026 |
| Thomas Catinazzo | Chief Financial Officer | Sep 9, 2026 |
| Sanjiv Patel | President and CEO | Sep 9, 2026 |
| Peter Rahmer | See remarks | Aug 28, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | Sanjiv Patel | Sale | 48,199 | $18.94 |
| Sep 8, 2026 | Sanjiv Patel | Sale | 48,199 | $18.94 |
| Sep 8, 2026 | Sanjiv Patel | Sale | 48,199 | $18.94 |
| Sep 8, 2026 | Sanjiv Patel | Sale | 48,199 | $18.94 |
| Sep 8, 2026 | Donald A Bergstrom | Sale | 8,530 | $18.97 |
| Sep 8, 2026 | Donald A Bergstrom | Sale | 8,530 | $18.97 |
| Sep 8, 2026 | Donald A Bergstrom | Sale | 8,530 | $18.97 |
| Sep 8, 2026 | Donald A Bergstrom | Sale | 8,530 | $18.97 |
| Sep 8, 2026 | Thomas Catinazzo | Sale | 17,717 | $18.94 |
| Sep 8, 2026 | Thomas Catinazzo | Sale | 17,717 | $18.94 |
| Sep 8, 2026 | Thomas Catinazzo | Sale | 17,717 | $18.94 |
| Sep 8, 2026 | Thomas Catinazzo | Sale | 17,717 | $18.94 |
| Aug 26, 2026 | Peter Rahmer | Sale | 4,508 | $20.03 |
| Aug 26, 2026 | Peter Rahmer | Sale | 4,508 | $20.03 |
| Aug 26, 2026 | Peter Rahmer | Sale | 4,508 | $20.03 |
RLAY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $15.36M | $-276.48M | -1.61 | $-235.46M |
| Dec 31, 2024 | $10.01M | $-337.71M | -2.36 | $-249.11M |
| Dec 31, 2023 | $25.55M | $-341.97M | -2.79 | $-300.32M |
| Dec 31, 2022 | $1.38M | $-290.51M | -2.59 | $-229.49M |
| Dec 31, 2021 | $3.03M | $-363.87M | -3.82 | $-74.41M |
Latest balance sheet: total assets $967.46M, total liabilities $77.45M, cash $121.19M (as of Jun 30, 2026).
RLAY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $19.75 |
| May 5, 2026 | 8-K Item 2.02 (results) | $13.00 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $9.16 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $6.53 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $3.49 |
| May 5, 2025 | 8-K Item 2.02 (results) | $3.32 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $3.75 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $6.25 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 22, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RLAY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.